RYTM Q4 2021 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M87.0% margin

Operating Income

-$51M-2806.2% margin

Net Income

-$43M-2359.2% margin

EPS (Diluted)

$-0.85

QoQ Revenue Growth

+76.8%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$41M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$330M

Total Liabilities

$45M

Stockholders' Equity

$284M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$2M	$0	—
Operating Income	-$51M	-$35M	-45.4%
Net Income	-$43M	-$35M	-22.8%